Pharmaceuticals

Recombinant Vaccines Market 2026–2030: Emerging Trends and Forecast Opportunities

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the recombinant vaccines market from 2026–2035 with trusted insights from The Business Research Company

How is the Recombinant Vaccines Market size predicted to change over the forecast window of 2026–2035?

The recombinant vaccines market has recently undergone rapid expansion. It is projected to increase from $15.79 billion in 2025 to $17.69 billion in 2026, at a compound annual growth rate (CAGR) of 12.0%. Historically, this growth can be attributed to the successful implementation of hepatitis B recombinant vaccines, long-standing global vaccination programs, increased awareness of viral diseases, greater investment in immunization funding, and regulatory endorsement for safer vaccine platforms.

The recombinant vaccines market is projected to experience significant expansion in the upcoming years, with its size predicted to reach $28.07 billion by 2030, showing a compound annual growth rate (CAGR) of 12.2%. Factors contributing to this growth during the forecast period include the increasing demand for precision vaccines, the development of vaccines for emerging diseases, the rise in adult booster vaccination initiatives, expanding global immunization reach, and a robust pipeline of recombinant vaccine candidates. Key trends anticipated in this period encompass an increase in recombinant subunit vaccines, the broadening of vector-based vaccine platforms, more extensive adult immunization campaigns, the development of combination recombinant vaccines, and a heightened emphasis on achieving long-lasting immunity.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33287&type=smp

Which Drivers Are Contributing To The Expansion Of The Recombinant Vaccines Market?

The increasing prevalence of infectious diseases is anticipated to propel the growth of the recombinant vaccines market. An infectious disease is defined as an illness caused by germs such as bacteria, viruses, fungi, or parasites, capable of spreading between individuals directly or indirectly. The rising occurrence of these diseases is attributed to inadequate sanitation and hygiene, as insufficient access to clean water, proper sanitation facilities, and effective waste management contributes to the easy transmission of harmful microorganisms through contaminated food, water, and personal contact, thereby escalating the risk of infections. Recombinant vaccines offer protection against infectious diseases by utilizing biologically engineered genetic material from pathogens to stimulate an immune response without causing actual illness. For instance, in July 2024, the Australian Institute of Health and Welfare, an Australia-based national agency, reported over 109,000 chlamydia and more than 40,000 gonorrhea notifications as the most commonly recorded sexually transmitted infections in Australia in 2023, along with more than 6,400 infectious syphilis cases, emphasizing the heightened incidence and persistent public health challenges. Consequently, the expanding prevalence of infectious diseases is a significant driver for the recombinant vaccines market’s growth.

What Segment Categories Are Covered In The Recombinant Vaccines Market?

The recombinant vaccines market covered in this report is segmented –

1) By Type: Subunit Vaccines; Vector-Based Vaccines

2) By Disease Indication: Human Papillomavirus (HPV); Herpes Zoster; Hepatitis B; Other Diseases

3) By Route Of Administration: Parenteral; Other Route Of Administrations

4) By End User: Pediatric; Adults

Subsegments:

1) By Subunit Vaccines: Protein Subunit Vaccines; Polysaccharide Subunit Vaccines; Conjugate Subunit Vaccines; Glycopeptide Subunit Vaccines; Recombinant Subunit Vaccines

2) By Vector-Based Vaccines: Viral Vector Vaccines; Non Viral Vector Vaccines; Replicating Vector Vaccines; Non Replicating Vector Vaccines; Bacterial Vector Vaccines

What Long-Term Trends Are Expected To Shape The Future Of The Recombinant Vaccines Market?

Leading companies in the recombinant vaccines market are concentrating on developing innovative vaccines, such as the recombinant 9-valent HPV vaccine, to achieve a competitive advantage. The recombinant 9-valent HPV vaccine provides protection against nine types of human papillomavirus (HPV) and is manufactured using recombinant DNA technology, signifying its laboratory production without live virus and its role in preventing HPV-related diseases like cervical cancer and genital warts. For instance, in August 2023, Jiangsu Recbio Technology Co. Ltd., a China-based biopharmaceutical company, moved its recombinant 9-valent HPV vaccine, REC603, through Phase III clinical follow-up, accompanied by ongoing 24-month observations. The vaccine showcased robust immunogenicity, a favorable safety profile, potential for scalable manufacturing, and long-term efficacy, thereby affirming its promise for extensive HPV prevention and commercialization.

Which Leading Companies Dominate The Recombinant Vaccines Market Share?

Major companies operating in the recombinant vaccines market are Johnson And Johnson, Merck And Co Inc., Pfizer Inc., Sanofi S. A., Novartis AG, AstraZeneca Plc, GlaxoSmithKline Plc, Mitsubishi Chemical Group Corporation, CSL Limited, Sinovac Biotech Ltd., Boehringer Ingelheim International GmbH, Zoetis Services Llc, Elanco Animal Health, BioNTech Se, Green Cross Corporation (Gc Biopharma), Bavarian Nordic A S, VBI Vaccines Inc., Vaxart Inc., Biological E Limited, Novavax Inc., Serum Institute Of India Private Limited, Vaxcyte Inc., Bharat Biotech International Limited, and Transgene S A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/recombinant-vaccines-market-report

How Does The Recombinant Vaccines Market Perform Across Major Global Regions?

North America was the largest region in the recombinant vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Recombinant Vaccines Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33287&type=smp

Browse Through More Reports Similar to the Global Recombinant Vaccines Market 2026, By The Business Research Company

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Ruminant Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/ruminant-vaccines-global-market-report

Vaccine Contract Manufacturing Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795